Reports FY22 revenue $1.414M vs $3M last year. "Since announcing positive topline results for the Phase 3 VIITAL study late last year, we have had multiple recent collaborative interactions with the FDA, and are continuing to work diligently toward completing and submitting our Biologics License Application for EB-101 in recessive dystrophic epidermolysis bullosa (RDEB)," said Vish Seshadri, Chief Executive Officer of Abeona. "We believe the VIITAL study results highlight the value that EB-101 could bring to RDEB patients as does the encouraging feedback we have received from our initial interactions with payors. In addition, we continue to make progress in our earlier stage programs that have the potential for treating serious eye diseases with new adeno-associated virus-based gene therapies, and we expect to keep advancing these toward an Investigational New Drug filing and clinical trials."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABEO:
- Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
- Abeona Therapeutics Announces New Employee Inducement Grants
- Abeona Therapeutics announces new employee inducement grants
- Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
- Abeona Therapeutics announces update on AAV ophthalmology program